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ABSTRACT
PRIYA CHETAN SANIPARA: Characterization of a Plasmid-Based DNA Vaccine for
Simian Immunodeficiency Virus (Under the direction of Dr. Wayne L. Gray)

Described as one of the world’s worst pandemics, HIV (Human
Immunodeficiency Virus) infects millions of people each year and is the cause for AIDS
(Acquired Immunodeficiency Syndrome). Despite the development of vaccines for
numerous infectious diseases such as polio, small pox, and influenza, a vaccine for HIV
remains elusive due to the virus’s high mutation rate and ability to evade the immune
system. HIV causes depletion of CD4+ lymphocytes, resulting in a weakened immune
system. However, the development of a plasmid-based DNA vaccine approach may help
revolutionize vaccine development for HIV due to its ability to confer cellular and
humoral immunity through T-cells and antibodies, respectively. The already constructed
pVAX1 plasmid’s small size and multiple cloning sites make it an effective vector for the
development of a plasmid-based DNA vaccine for HIV. In this experiment, a gene
sequence for SIV (Simian Immunodeficiency Virus) proteins inserted into the pVAX1
plasmid was transfected into an African green monkey kidney cell line (Vero cells) for
expression of SIV proteins.
HIV and AIDS research aims to contribute to the development of prevention and
treatment strategies for this disease. The research in this thesis focuses on
characterization of a plasmid-based DNA vaccine expressing rev, tat, and nef (Retanef)
proteins for SIV using restriction endonuclease analysis, PCR, immunofluorescence, and
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western blotting. The specific aims for this thesis include: evaluating the presence of the
Retanef gene sequence inside pVAX-RTN, and analyzing the expression of the Retanef
protein in vitro. This study showed that transfection of pVAX-RTN into Vero cells
resulted in successful expression of the Retanef protein. Detection of the Retanef protein
by SIV positive monkey sera also showed positive results, further proving that Retanef is
expressed inside Vero cells via the pVAX-RTN plasmid.
The results acquired in this experiment will contribute towards HIV vaccine
research by using SIV as the experimental model for HIV. The results acquired in this
research supports the use of early regulatory proteins in SIV vaccines and will be
contribute towards successfully creating an effective HIV vaccine in the future.
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INTRODUCTION

Throughout history, ever since the first humans spread across the world,
outbreaks of infectious disease have been common. Only a few of these outbreaks have
been able to reach a pandemic level, such as smallpox, bubonic plague, and the Spanish
flu. As scientists developed a better understanding of disease transmission and
mechanism of action, many of these diseases were eradicated or prevented from
occurring again by means of proper sanitation, prevention, and treatment. Over the years,
the development of vaccines has better prepared us to face diseases and the challenges
they bring. However, creating a vaccine involves an incredible amount of time and effort,
and new diseases are accompanied with their own unique challenges. Discovered in the
1980s, HIV (Human Immunodeficiency Virus) has become a pandemic, infecting
millions of people around the world. Without treatment, HIV weakens the immune
system and progresses to AIDS (Acquired Immunodeficiency Syndrome), which leaves
the affected individual vulnerable to opportunistic infections. Effective treatments for
HIV only maintain the viral particles at a manageable level; the affected individual has to
live with HIV for the rest of their life. The development of a vaccine for HIV is crucial to
slowing the spread of this disease and preventing new infections. The research conducted
in this thesis will contribute towards vaccine development in the global fight against
HIV/AIDS.
This project uses SIV (Simian Immunodeficiency Virus) as a model for HIV for
the characterization of a plasmid-based DNA vaccine. A previously constructed plasmid
1

containing the gene sequence for SIV early regulatory (rev and tat) and accessory (nef)
proteins was analyzed for expression in African green monkey kidney cells (Vero cells).
The features of the vaccine were analyzed using various lab techniques as follows:
- Restriction endonuclease analysis was used to determine the size of the Retanef
gene sequence within the plasmid.
- PCR and gel electrophoresis was used to determine the orientation of the Retanef
gene sequence within the plasmid.
- Immunofluorescence was used to determine the expression and localization of the
desired Retanef protein within the transfected Vero cells.
- Western Blotting was used to identify the protein within the transfected Vero cells.
Characterizing this vaccine and evaluating the expression of the desired antigen within
Vero cells will contribute towards the possibility of using this vaccine in trials using nonhuman primate models.
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CHAPTER 1: BACKGROUND ON HIV/AIDS

In 1981, the Centers for Disease Control and Prevention’s Morbidity and
Mortality Weekly report first described Acquired Immunodeficiency Syndrome (AIDS)
in five homosexual men diagnosed with an opportunistic infection of Pneumocystis
carinii pneumonia in California (De Cock et al., 2011). The disease was also later
identified in heterosexual individuals receiving blood products and babies born to
infected mothers (Piot & Quinn, 2013). Although the causative agent was yet to be
identified, preventative methods based on risk groups and modes of transmission were
already being implemented. Since the discovery of the Human Immunodeficiency Virus
(HIV) in 1983 as being the etiologic agent for AIDS, public health organizations have
made many advances in treatment, screening, and prevention of AIDS. Despite these
efforts, a vaccine for HIV is not yet available, and AIDS remains one of the world’s
worst pandemics (De Cock et al., 2011).
As of 2018, there were 37.9 million people in the world living with AIDS, with an
average of 1.7 million new infections occurring each year. However, only 21% of those
individuals had access to HIV testing, and only 62% had access to antiretroviral therapy.
The majority of individuals affected by this disease are from low or middle-income
countries that do not have access to proper HIV prevention and treatment. HIV testing
and treatment are crucial to preventing the progression to AIDS and ending transmission
of the virus. Despite these setbacks, AIDS-related deaths had decreased from 1.2 million
3

in 2010 to 770,000 in 2018. With more efforts to increase access in resource-poor
countries and investment in HIV/AIDS research by the NIH, more progress is being made
towards more effective treatments and a cure (“Global HIV/AIDS Overview”).

Origin and Emergence of HIV/AIDS
AIDS is caused by the human immunodeficiency virus (HIV), a Lentivirus in the
family Retroviridae that is closely related to simian immunodeficiency virus (SIV). There
are two types of HIV (HIV-1, HIV-2), and each one is thought to have originated via
cross-species infection of a simian precursor from non-human primates to humans. The
African green monkey was the first species to be found infected with SIV. Nonpathogenic to the host species, SIV primarily infects monkeys and is species-specific
(Sharp & Hahn, 2011). However, the virus is pathogenic if it infects a non-host species.
For example, chimpanzees may have acquired 𝑆𝐼𝑉𝑐𝑝𝑧 via a recombination event resulting
from cross-species transmissions of SIVs by two different monkey species. Greater spotnosed monkeys are the natural reservoir for 𝑆𝐼𝑉𝑔𝑠𝑛 , and red-capped mangabeys are the
natural reservoir for 𝑆𝐼𝑉𝑟𝑐𝑚 . Chimpanzees may have acquired these two SIVs by
predation which resulted in the two viruses recombining to form a virus capable of also
infecting humans, 𝑆𝐼𝑉𝑐𝑝𝑧 . This virus then evolved to HIV-1 as a result of host adaptation.
Although similar in structure, HIV-1 and HIV-2 differ in their evolutionary pathways and
pathogenicity. HIV-2 is less pathogenic and is closely related to 𝑆𝐼𝑉𝑠𝑚𝑚 , a virus naturally
infecting West African sooty mangabeys. In a similar cross-species transmission event,
HIV-2 is thought to have originated by humans getting infected with 𝑆𝐼𝑉𝑠𝑚𝑚 , and the
virus adapting to the host to form HIV-2 (Sharp & Hahn, 2010). Surprisingly, there is
4

also evidence of cross-species transmission of SIV between chimpanzees and gorillas,
resulting in 𝑆𝐼𝑉𝑔𝑜𝑟 . Scientists have yet to discover how this virus was transmitted because
gorillas are herbivores (Sharp & Hahn, 2010).
Additionally, each type of HIV has multiple sub-types resulting from independent
cross-species transmission events. The sub-types of HIV-1 include group M, N, O, and P,
with M being the pandemic form and accounting for the majority of AIDS cases. Group
O and N are less prevalent than group M, and infections involving these subtypes are
mainly found in Cameroon. Group P is even less prevalent; the virus was only found in
two individuals from Cameroon. Less likely to progress to AIDS and with lower
transmission rates, HIV-2 consists of groups A and B (Sharp & Hahn, 2011).

HIV Viral Transmission
HIV is primarily transmitted through exposure to infected bodily fluids or blood
via injured skin or mucosa. This can be through blood transfusions, organ transplants,
sexual intercourse, breastmilk, childbirth, or contaminated needles (German Advisory
Committee Blood, 2016). However, since the majority of HIV cases are the result of
transmission via sexual intercourse, HIV is classified as a sexually transmitted disease
(STD) (Sharp & Hahn 2011). Although less common, HIV is also transmissible by
contact with an infected person’s saliva to open legions and bite injuries. The chances of
infection increase if the infected individual’s virus titers are higher. Additionally,
pregnant women can transmit the infection to the baby during the last trimester or earlier,
depending on viral titers. Although HIV could be considered a zoonotic disease in the
early part of the 20th century, it is currently only transmissible between humans.
5

Therefore, HIV is not transmitted via animal vectors; it is also not spread by food or
water (German Advisory Committee Blood, 2016).

HIV Viral Structure
HIV has many key proteins that assist in viral entry, and it is important to
understand their function before discussing pathogenesis. HIV is 100 nm in diameter and
is composed of an outer lipid bilayer, which functions as the envelope and assists the
viral particle with entry into the host cell. The envelope of the virus contains spikes
formed by trimers of a surface protein (gp120), which are attached to the membrane by
trimers of a transmembrane protein (gp41). The inner viral capsid is composed of a
capsid protein (p24), and the outer capsid membrane is assembled by a matrix protein
(p17). The core of the virus contains two single-stranded RNA molecules with enzymes
that assist in viral replication. Additional regulatory and accessory proteins such as rev,
tat, nef, vif, vpr, and vpu contribute to viral production and pathogenicity (German
Advisory Committee Blood, 2016). The HIV genome and structure of SIV-Retanef is
shown in Figure 1.
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(A)

(B)
Figure 1 – Structure of SIV genome and Retanef Sequence - (A) – Structure of SIV
Genome – The structure and organization of reading frames encoding the genes for the
various structural and regulatory proteins. Notice that the rev and tat are composed of
two gene regions. (B) - Structure of RTN sequence - Schematic representation of the
chimeric Retanef protein. C: carboxy terminus of the protein; N: amino terminus. The
sequences for rev and tat were separated and rearranged to disrupt the functionality of
these two proteins. A partial sequence for tat was inserted between the two separated nef
sequences to prevent nef from rearranging itself back to its pathogenic form. Figure A is
adapted from, “New Strain of Simian Immunodeficiency Virus Identified in Wild-Born
Chimpanzees from Central Africa” - Scientific Figure on ResearchGate. Available from:
https://www.researchgate.net/figure/The-Amplification-strategy-and-the-genomestructure-of-the-new-SIVcpz-identified_fig7_230865090 [accessed 28 Apr, 2020]Figure
B is adapted from ‘A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component
of an SIV/HIV vaccine,” by Zdeněk Hel, Julie M. Johnson, Elzbieta Tryniszewska, WenPo Tsai, Robert Harrod, Jake Fullen, JimTartaglia, and Genoveffa Franchini, 2002,
Vaccine, 20, 3174.
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HIV Viral Replication
HIV targets CD4+ T cells and gains entry by attaching to the CD4+ receptor on
the surface of these cells (Naif, 2013). This internalization occurs via the surface protein,
gp120. This action triggers a series of conformational changes that assist in viral
attachment to the host cell. The virus is then able to bind to a chemokine co-receptor,
which triggers an irreversible conformational change that results in the formation of a
pore by gp41. The subsequent fusion of the viral envelope to the plasma membrane
releases the viral capsid into the cytoplasm of the host cell (Simon et al., 2006). In the
cytoplasm, the virus uses its reverse transcriptase to transcribe its RNA genome into
proviral DNA. Finally, the proviral DNA is transported to the nucleus and integrated into
the host cell genome via an integrase., establishing latency. HIV viral reverse
transcriptase has no proofreading activity, which causes additional mutations in the
proviral DNA. These mutations lead to viral particles with variant genomes that are able
to evade the immune system, resulting in a sustained infection (German Advisory
Committee Blood, 2016).

HIV Illness & Symptoms
HIV is a chronic infection that causes a depletion of CD4+ lymphocytes, which
leads to a weak immune system resulting in a variety of non-specific symptoms. During
the initial symptomatic phase, which lasts 2-6 weeks, infected individuals will show nonspecific symptoms similar to EBV or CMV induced mononucleosis. More serious
symptoms can include aseptic meningitis, meningismus, and photophobia. Individuals
may also present with early symptoms including lymphadenopathy, or oral
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manifestations such as leukoplakia, thrush, or periodontal disease. Viral titers are highly
infectious during this time. However, during the asymptomatic period, the virus enters a
latent period, and the majority of patients will not show signs or symptoms until years
after exposure to HIV. Even though viral titers are low during the asymptomatic period,
individuals may still unknowingly spread the disease. Since there is a broad range of
early signs and symptoms, physicians must be vigilant in assessing patient history and
risk factors to recognize an HIV infection before it manifests into AIDS. (Miedzinski,
1992).
If left untreated, HIV can cause significant CD4+ cell depletion that can lead to
AIDS within 10 years from initial infection (German Advisory Committee Blood, 2016).
This weakened immune system leaves the body susceptible to opportunistic infections
such as Pneumocystis carinii pneumonia (PCP), which is an indicating factor for AIDS.
Additionally, patients can contract tuberculosis, which can be fatal in
immunocompromised individuals. Neurologic effects include AIDS dementia complex,
which occurs in 60% of AIDS cases. These diseases are the indirect result of an HIV
infection, and many deaths occur due to the secondary opportunistic infections caused by
a weakened immune system. Another sign that is indicative of AIDS is Kaposi’s
sarcoma, a malignant cancer that causes nodules on mucous membranes, or any organ
(Miedzinski, 1992).

HIV Diagnosis
During the initial asymptomatic phase, infected individuals will not show any
symptoms. Due to this reason, the early recognition ofpotential infections are made by
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assessing the patient’s risk factors such as intravenous drug use, sexual contact, or
exposure to blood products. During this phase, a test for the p24 HIV core antigen can be
conducted in the early stages if the assessment of risk factors forms enough evidence to
suspect an infection (Miedzinski,1992). Primary screening for HIV occurs by testing for
antibodies against the virus or detecting the virus. Antibody or antigen detection by using
a serological test is more commonly used because it is rapid and can be done on various
bodily fluids such as plasma, blood, or saliva. However, these tests are not effective when
the virus is in the latent phase because no antibodies are present. Babies born to mothers
who are infected will have maternal HIV antibodies, and a test may result in a falsepositive. In these situations, the viral DNA in the host’s genome has to be detected using
RT-PCR (Simon et al., 2016). Current methods of HIV antibody are sensitive enough to
detect the virus within 1-2 weeks of infection, which allows the individual early access to
treatment and prevents further transmission of HIV (Zulfiqar et al., 2017).
In order to determine the severity of the infection and progression towards AIDS,
physicians have to determine the stage of the disease by measuring CD4+ cell count and
plasma viral load using flow cytometry. Other symptoms associated with opportunistic
infections are also evaluated. The time between specimen collection and laboratory
assays should be minimal, so dried blood samples are used to counteract problems
associated with the transportation of specimens. However, communities, where resources
are limited, need more cost-effective methods for analysis such as dipstick assays, total
white-counts, or CD4+ chips (Simon et al., 2006).
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HIV Treatment and Prevention
The current treatments for HIV do not eradicate the virus. Instead, the treatments
help prevent the progression of HIV to AIDS and HIV infection to high-risk individuals.
Initially, HIV was treated with only one antiretroviral drug. As the development and
discovery of HIV drugs increased to include various inhibitors of HIV essential enzymes,
more drugs started to be used in combination. This combination drug therapy became
known as HAART (highly active antiretroviral therapy). The main goal of this therapy is
to increase the strength of the immune system by reducing viral load and increasing
CD4+ T lymphocytes (Zulfiqar et al., 2017). This treatment is effective in controlling
viral multiplication and prolongs the asymptomatic stage of the infection resulting in
lower risk of transmission and progression to AIDS (Bhatti et al., 2016). Because HIV
manifests various symptoms in different individuals, the drug combinations are modified
according to the patient. Normally, HAART involves a combination of three drugs,
which can include reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors,
chemokine receptor 5 antagonists, or integrase transfer inhibitors. Each of these drugs
targets viral entry, integration of viral DNA into the host’s genome, or the production and
assembly of the virus. HAART is recommended for all HIV patients regardless of the
CD4+ lymphocyte count, and adherence to the regimen is recommended to prevent drug
resistance and viral rebound (Bhatti et al., 2016).
HIV can be prevented by avoiding high-risk behaviors such as intravenous drug
use, multiple sexual partners, and unprotected sex. For high-risk individuals, another
option is pre-exposure prophylaxis (PrEP), which is used in uninfected individuals before
potential exposure to HIV. This treatment prevents HIV infection by inhibiting viral
11

replication once the virus enters the body, and it prevents HIV from establishing a
permanent infection. Truvada, which is a combination of two drugs, is usually the drug of
choice for PrEP (Marfatia et al., 2017). When taken consistently, PrEP is an effective
way to prevent new HIV infections (Eakle et al., 2018). Post-exposure prophylaxis (PEP)
is used in emergencies after exposure to potentially HIV infected individuals or needles.
PEP should be used within 2 to 72 hours of HIV exposure for maximum efficacy and
continued for 28 days post-exposure. PrEP and PEP are useful treatments for the
prevention of HIV infection when used correctly and consistently (Marfatia et al., 2017).

12

CHAPTER 2: PLASMID-BASED DNA VACCINES
Current vaccination strategies involve using vaccines containing live, attenuated
viruses, killed pathogens, or viral subunits. Killed pathogens provide immunity through
the humoral response by mobilizing CD4+ lymphocytes; however they do not provide
permanent immunity. Live, attenuated vaccines provide both cellular and humoral
immunity, and they provide life-long immunity. However, there are disadvantages to live,
attenuated vaccines as well. A live, attenuated vaccine only targets a specific viral
subtype, therefore it is not effective against a virus with multiple subtypes. Additionally,
the degree of attenuation affects the strength of the immune response. There is also the
risk of an attenuated vaccine recovering virulence and causing disease. Due to these
limitations, scientists were driven to develop new vaccination strategies such as DNA
vaccines (Ferraro et al., 2011).
Background
DNA vaccines became of interest in 1990, when it was discovered that plasmid
DNA could induce immune responses to viral and nonviral antigens. Initial clinical trials
included DNA vaccines against HIV, influenza, human papillomavirus, hepatitis, and
malaria. However, these first generation DNA vaccines produced low CD4+ and CD8+
lymphocyte responses resulting in poor immunogenicity. This low immunogenicity was
hypothesized to be from inefficient plasmid delivery methods. Following these results,
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many improvements were made to optimize transfection efficiency, which led to the
development of second-generation DNA vaccines (Ferraro et al., 2011).
In contrast to the conventional vaccines, DNA vaccines contain genes for a
particular antigen rather than the antigen itself. This way, the protein produced by the
gene sequence can be introduced into the MHC class 1 processing pathway for
presentation to CD8+ lymphocytes. With DNA vaccines for HIV, the viral RNA is
converted to DNA, which is then inserted into a bacterial plasmid. This plasmid is then
introduced into a bacterial vector where it can be used as a vaccine and be administered
intramuscularly. After administering the vaccine, the plasmid is taken up by the cell’s
nucleus, where the promoter will initiate transcription, which is followed by protein
production. These proteins mobilize T cells and antibodies that will destroy the virus.
Since these proteins are created inside the cell, they are also exposed to different antigen
processing pathways that involve MHC class I molecules, thus expanding vaccines to
include cellular responses as well as humoral responses (Donnelly et al., 2005).

DNA Vaccines for HIV
Developing a vaccine against HIV produces several unique challenges. The
conserved receptor and co-receptor bindings sites that assist in viral attachment are
covered in a glycosylated residue, which allows the virus to evade antibodies.
Additionally, HIV is able to integrate into the host’s genome and become latent, which
allows the virus to escape the immune system. The high error rate of the reverse
transcriptase has resulted in at least 12 viral subtypes, adding to the challenge of creating
a universal vaccine (Gira et al., 2004).
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Due to the high mutation rate and the complex nature of HIV, an effective vaccine
for HIV requires cellular and humoral responses. Several vaccine trials have tested the
heterologous prime-boost method, which combines a DNA-based and viral-based vaccine
with a recombinant protein vaccine (Ferraro et al., 2011). The addition of a DNA vaccine
induces a broader T-cell response, which is important in combating an infection that
primarily infects helper T-cells (Donnelly et al., 2005). Currently, a trial determining the
safety of an DNA vaccine containing HIV genes for gag, pol, and env is underway
(Ferraro et al., 2011).

Specific Aims for this Experiment
This experiment involves using pVAX, a plasmid approved for use in developing
DNA vaccines, with the gene sequence for SIV proteins. This gene sequence is
collectively called Retanef, and is composed of genetically modified and re-assorted
sequences for rev, tat, and nef proteins. These three proteins are expressed early in the
viral life cycle, and their recognition may increase the elimination of infected cells by the
immune system. The frequency of T-cell recognition of these three proteins was also
shown to be higher than reverse transcriptase, env gp41, and gp120 proteins. The Rev
protein contributes to viral replication, and the Tat protein down-regulates MHC class II
proteins while promoting T-cell apoptosis. Tat also transactivates multiple genes that may
contribute to the development of AIDS-related tumors. Nef is especially important to
pathogenicity because it down-modulates MHC class I surface proteins, which
contributes to viral evasiveness to the immune system by protecting virus-infected cells
from apoptosis. Partially deleted Nef protein is able to re-arrange itself back into a
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pathogenic form. By including the sequence for the Nef protein in this vaccine,
recognition of the infected cells may occur before Nef down-modulates the MHC class 1
surface proteins and allow the immune system to clear the infected cells. The effect of
these early regulatory genes on the host’s MHC molecules indicates the importance for
their inclusion in a vaccine that aims to increase immune T-cell response (Hel et al.,
2002).
The structure of the Retanef coding sequence contains rev, tat, and nef SIV gene
sequences. The rev and tat sequences are split into two segments to disrupt their
functionality. The C-terminal part of the tat sequence is placed in between the C-terminal
and N-terminal part of the nef sequence. The nef sequence was separated by the tat
sequence to prevent the recombination of nef into its pathogenic form. An HA-tag was
attached to C-terminal end of the entire sequence to facilitate the detection of the protein
using antibodies. These details can be seen in Figure 1.
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CHAPTER 3: METHODS
The methods in this thesis were used to qualitatively characterize a previously
constructed pVAX1(Thermo-Fisher Scientific) vector (Figure 2) with SIV-retanef
proteins using PCR (Polymerase Chain Reaction), immunofluorescence, and western
blotting. The pVAX1 vector is specifically constructed for use in the development of a
DNA vaccine. The plasmid vector is 3.0kb in size with a CMV(cytomegalovirus)
promoter, which ensures a high level of expression in various mammalian cells. The
plasmid vector has multiple unique cloning sites, however, the SIV-retanef gene has been
inserted near the BamH1 restriction site, making it the point of interest in this study. SIV
–retanef has been constructed by re-assortment of the rev, tat, and nef open-reading
frames of SIV. There is also an HA (hemagglutinin) tag that has been inserted at the end
of the SIV-retanef gene sequence for antibody detection during immunofluorescence or
western blotting. There are two pVAX1-RTN (pVAX1-Retanef) clones that have been
previously constructed with the SIV-retanef gene sequence in opposite orientations to the
CMV promoter. The experiments conducted in this thesis analyze the orientation of the
SIV-retanef gene in these two clones via PCR and successful expression of the protein by
transfection into African green monkey kidney cells, also called Vero cells. The
expression of the protein was analyzed by using immunofluorescence and western
blotting.
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Figure 2- Structure of the PVAX1 vector – This figure shows the gene for Kanamycin
resistsance, the location of the CMV promoter inside the pVAX1 vector., and the BamH1
restriction site. The size of the plasmid is 3.0 kb , and the size of the RTN protein is 1.486
kb or 55kDa.(https://www.thermofisher.com/order/catalog/product/V26020#/V26020)

Restriction Endonuclease Analysis of pVAX-RTN and PCR analysis of RTN

A restriction digest using BamHI, a restriction endonuclease, was used to isolate
the gene sequence with SIV-retanef from the rest of the plasmid for pVAX-RTN clones 1
and 2. Five 𝜇𝐿 of pVAX-RTN clone 1 was added to an eppendorf tube along with two
𝜇𝐿 of CutSmart buffer, 1 𝜇𝐿 of BamHI, and 12 𝜇𝐿 of distilled water. This process was
repeated for pVAX-RTN clone 2, and the two tubes were added to a water bath at 37℃ to
cut overnight.
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The following day, both pVAX-RTN clones were loaded onto a trisborate gel
with a molecular weight ladder for gel electrophoresis. After completion, the gel was
observed under an imager, which allowed visualization of results by showing the size of
the cut pVAX vector and the SIV-retanef gene sequence in each of the two clones.
In order to determine the orientation of the SIV-retanef gene sequence, a PCR
with forward and reverse primers for SIV-Retanef was conducted for both pVAX-RTN
clones. Three PCR tubes were used with tube 1 containing, pVAX-RTN clone 1, CMV
primer sequence, and a reverse RTN primer. Tube 2 contained pVAX-RTN clone 1,
CMV primer sequence, and a forward RTN primer. Tube 3 contained pVAX-RTN clone
2, reverse RTN primer, and a forward RTN primer. The amount of DNA and primer
sequences used in each tube was 2 𝜇𝐿. All three tubes contained 25 𝜇𝐿 of the Bio Taq
mix, and 19 𝜇𝐿 of distilled water. A PCR was run on each tube, and this was repeated for
pVAX-RTN clone 2.

Detection of SIV-Retanef Protein in Vero Cells via Immunofluorescence
Before starting the protocol for immunofluorescence, both pVAX-RTN clones
were sent for gene sequencing to Eurofins, which verified the presence of a gene
sequence of an HA tag for 1° antibody (Appendix A). The sequence also verified that the
gene sequence inserted into the pVAX plasmid in both clones was indeed SIV-Retanef.
Next, pVAX-RTN clones 1 and 2 were transfected into Vero cells using the Superfect
reagent (Invitrogen) before observation under a Zeiss microscope using the
immunofluorescence settings.
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It is important to mention that before deciding to use a 4-well permanox chamber
slide to transfect the Vero cells, a 96-well plate and 8-well chamber glass slide were also
used. However, observation under a microscope using a 96-well plate did not produce
conclusive results. The 8-well chamber glass slide resulted in the infected Vero cells
peeling off the slide before antibody detection could occur. After trial and error, a 4-well
permanox chamber slide produced successful adherence of infected Vero cells.
A 4-well permanox chamber slide was seeded to confluence with the outer two
chambers having 40,000 and 60,000 cells each. The two middle chambers had 50,000
cells each. All chambers were filled with 500 𝜇𝐿 of cell media and placed in a 𝐶𝑂2
incubator. The chamber with 40,000 cells was used as negative control for cell
transfection, therefore it was not transfected with the either pVAX-RTN clone. Since
pVAX-RTN clone 1 could not express the SIV-retanef protein because the gene sequence
was oriented in the backwards direction, it was used as a negative control for protein
expression and only added to one chamber with 50,000 cells. The last two chambers with
50,000 and 60,000 cells, respectively, were used for pVAX-RTN clone 2, which had the
SIV-retanef gene sequence in the forwards direction.
The following methods explain the protocol for one chamber as per the
manufacturer’s directions for Superfect. Firstly, Optimem was used to dilute 1 𝜇𝑔 of the
plasmid DNA to a total volume of 60𝜇𝐿. The concentration of plasmid DNA for clone 1
and 2 was 0.5𝜇𝑔/𝜇𝐿 each, so a 2𝜇𝐿 solution of each was used to obtain 1𝜇𝑔 of plasmid
DNA. Next, 5𝜇𝐿 of Superfect was added to the plasmid DNA and optimum solution and
mixed. This mixture was incubated at room temperature for 5-10 minutes. While the
plasmid DNA-superfect complex formation was taking place, the growth medium was
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aspirated from the 4-well permanox chamber slides. The cells in the chamber slide were
washed once with 300𝜇𝐿 of 5% PBS. After adding and mixing 350𝜇𝐿 of cell media
without trycine to the plasmid DNA-Superfect complexes, the total volume was
transferred to the chamber slide. The cells with the transfection complexes were
incubated for 3 hours at 37℃ in a 𝐶𝑂2 incubator. Afterward, the medium with remaining
transfection complexes was removed, and the cells were washed once with 350𝜇𝐿 PBS.
Finally, 500𝜇𝐿 of cell media was added to the cells before incubating at 37℃ in a 𝐶𝑂2
incubator for at least 48 hours.
After the incubation time was complete, the cells were fixed onto the slide in
preparation for visualization using antibodies. After the cell media was removed from
each chamber, 500 𝜇𝐿 of 4% paraformaldehyde was added to each chamber and
incubated for 20 minutes at room temperature. Next, the paraformaldehyde was removed,
and the cells were permeabilized with 500 𝜇𝐿 of 0.2% triton x-100 for 10 minutes at
room temperature. The triton x-100 was removed before adding 500 𝜇𝐿 per chamber of
1% BSA in PBS to block the cells overnight in the fridge at 4℃.
Next, the blocking buffer was removed from the cells, and the antibody dilutions
were prepared. The 1° antibody used was an HA-tag monoclonal antibody designed to
identify and adhere to the hemagglutinin tag on the expressed SIV-retanef protein. A
1:100 dilution was made with this antibody and 1% BSA in PBS before adding 100 𝜇𝐿 to
each chamber. The cells were then incubated for 2 hours at room temperature. After the
1° antibody dilutions were removed and the cells washed four times with 1X PBS, the 2°
antibody dilutions were prepared using a goat anti-mouse antibody conjugated to FITC.
All of the steps involving the 2° antibody were conducted in the dark due to the FITC
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label’s sensitivity to light. The 2° antibody was diluted in a 1:1000 ration using 1% BSA
in PBS, and the cells were incubated with 100 𝜇𝐿 of this dilution for 1 hour. After
removing the 2° antibody and washing the cells again with 1X PBS, the cells’ nuclei
were stained with DAPI for 5-10 minutes. Lastly, the cells were washed again with 1X
PBS after removing DAPI. The chamber walls were removed, and the slide was prepped
with 70% glycerol and a coverslip for observation under the Zeiss scope for
immunofluorescence.
Identification of SIV-Retanef Protein via Western Blotting
Vero cells were transfected with pVAX-RTN clones 1 and 2, and the protein
expressed by the SIV-retanef gene was isolated and identified using western blotting.
Vero cells were seeded in two 25𝑐𝑚2 flasks. One flask was seeded with 16 × 105 cells,
and transfected with pVAX-RTN clone 1. Another flask was seeded with 8 × 105 cells
and transfected with pVAX-RTN clone 2. The same Superfect transfection protocol was
used to transfect the cells with the measurements adjusted according to the size of the
flasks.
After transfection, the cells in each flask were solubilized with 500𝜇𝐿 of a 1:10
mixture DTT and protein solubilization buffer. The solubilized cells were transferred to
separate tubes and placed in boiling water for 5 minutes. Next, the cells in both tubes
were centrifuged for 5 minutes at 21,000xg in preparation for an SDS-PAGE, a common
procedure used to separate proteins based on mass. The protein samples and molecular
weight ladder were run on a 10% tris-glycine gel for 75 minutes at 100V and 60mA. The
order that the proteins and molecular weight ladder were loaded is shown in Figure 3.
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After separating the proteins on a gel, the samples were transferred to a PVDF
membrane for antibody detection. Before starting the western blot, the blotting sponges
and filter paper were soaked in 1X transfer buffer. The PVDF membrane was soaked in
methanol for 30 seconds and washed with distilled water for 3-5 minutes. After the SDSPAGE ended, the gel sandwich was assembled by putting the PVDF membrane on the
gel. Afterward, the filter paper was added to the gel and the PVDF side of the sandwich.
The blotting sponges were then placed on each side of the sandwich, covering the filter
paper. This sandwich was then clamped inside a cassette, and the blotting transfer was
run for 75 minutes at 20V and 180mA. After the transfer was complete, the PVDF
membrane was washed with distilled water two times for 5 minutes each.
Before starting the chemiluminescence immunoassay, the PVDF membrane with
the samples was washed with 100% methanol for a few seconds and washed with
distilled water. Then, the membrane was blocked overnight in 5% blotto blocking buffer
at 4℃. The next day, the 1° antibody was diluted 1:200 in 5% blotto blocking buffer. The
primary antibody used was the HA-tag anti-mouse monoclonal antibody, and the
membrane was incubated with this antibody at room temperature for 3 hours on a
gyratory shaker. Afterward the 1° antibody was removed, and the membrane was washed
with 1X PBS five times for 5 minutes each. Next, a 1:1000 dilution of 2° antibody and
5% blotto blocking buffer was placed on the membrane and incubated for 1 hour at room
temperature on a gyratory shaker. The 2° antibody used was an HRP (horse radish
peroxidase) conjugated goat-anti-mouse antibody. Next, the membrane was washed with
1X PBS five times for 5 minutes each. Next, a 1:1 solution of luminol and peroxide
substrate was added to the membrane for 5 minutes to react with the horse radish
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peroxidase enzyme, which emits light and is detectable by the Biorad Chemidoc Imager.
The “high resolution” program was used to expose the membrane to light for five
seconds, capturing an image every second.

Figure 3 - Sequence of samples prior to performing SDS-PAGE. Molecular weight
ladder was always loaded before loading pVAX-RTN clones 1 and 2. This PVDF
membrane provided 3 blots, 2 of which were used in a later experiment with other
antibodies.

Western Blotting using SIV positive monkey serum
The remaining blots from the previous western blot were used to do a
chemiluminescence immunoassay using SIV positive serum from a monkey challenged
with the macaque strain of SIV (SIVmac251) as the 1° antibody, and the 2 ° antibody was
HRP-conjugated anti-monkey. SIV negative monkey serum was used as the 1° antibody,
and the same 2 ° antibody was used. The same methods for a chemiluminescence
immunoassay were followed, as mentioned in the Methods for western blotting.
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RESULTS
Restriction Endonuclease Analysis of pVAX-RTN
The purpose of restriction endonuclease analysis of pVAX-RTN was to confirm
the presence of the gene encoding Retanef in the BamH1 restriction site. After cutting the
pVAX-RTN clones 1 and 2 with BamH1 restriction endonuclease and running the
resulting samples on a trisborate gel, the results showed two bands. The 3.0kb band
indicates the larger remaining sequence from the cut pVAX-RTN plasmid. The 1.5kb
band indicates a shorter sequence within the BamH1 restriction site on the pVAX
plasmid. These results shown in Figure 4 confirm that the Retanef gene sequence was
inserted into the BamH1 restriction site on pVAX-RTN clones 1 and 2.
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2

Cut pVAX plasmid – 3.0kb
Cut RTN sequence – 1.5kb

Figure 4 – Gel electrophoresis of pVAX-RTN clones 1 and 2 cut with BamHI. A
molecular weight ladder was loaded before the pVAX-RTN clones. After cutting each
clone with BamHI, the samples were loaded onto a trisborate gel for electrophoresis.
Lane 1 contains pVAX-RTN clone 1, and lane 2 contains pVAX-RTN clone 2.

pVAX-RTN clone 1 – Backwards Orientation
CMV Primer

RTN Rev Primer

CMV promoter

STOP

RTN Fwd Primer

poly-A-RTN

ATG

pVAX-RTN clone 2 – Forwards Orientation
CMV Primer

CMV promoter

RTN Fwd Primer

ATG

RTN Rev Primer

RTN-poly-A

STOP

Figure 5 – PCR data using RTN forward and reverse primers. The figure above
shows the orientation of the RTN forward and reverse primers for PCR analysis. The
purpose of the PCR was to determine the orientation of the RTN gene sequence relative
to the CMV promoter. The sequence in the backwards orientation was used as the
negative control.
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PCR analysis of SIV-RTN in pVAX-RTN
PCR was conducted to confirm that the 1.5kb gene sequence in pVAX-RTN
clones 1 and 2 is the gene sequence for SIV-RTN. The use of RTN specific primers
during PCR produced results that confirmed that the 1.5kb gene sequence inside clones 1
and 2 is SIV-Retanef. These results are shown in Lane 3 in Figures 6 and 7 where the
forward and reverse RTN primers were used. The results in Lane 3 in Figures 6 and 7
confirm that the 1.5kb sequence is RTN in pVAX-RTN clones 1 and 2.
The RTN sequence inserted into the pVAX plasmid can be in the forwards or
backwards orientation with respect to the CMV promoter. A PCR analysis with the
specific combination of the primer for the CMV promoter, forward RTN primer, and
reverse RTN primer was used to determine the orientation of the RTN sequence inside
each clone. After running a PCR with specific RTN primers, and the specific pVAXRTN clone, the resulting samples were run on a trisborate gel. Figure 6 shows the results
for pVAX-RTN clone 1. Lanes 1 and 2 contained the experimental samples while lane 3
contained forward and reverse RTN primers. The results for the PCR sample in lane 1
with pVAX-RTN clone 1, CMV primer, and reverse RTN primer were inconclusive.
Lane 1 does not have a definitive band throughout the gel. Lane 2 contains the PCR
results for pVAX-RTN clone 1, CMV primer, and the forward primer; this lane shows a
definitive band, which indicates that using a forward primer results in a successful
amplification of pVAX-RTN clone 1. Lane 3 contains both forward and reverse primers
for RTN, and the results show a clear band. The results shown in Figure 6 in Lane 2 and
Lane 3 indicate that the RTN sequence in pVAX-RTN clone 1 is backwards relative to
the CMV promoter, and the 1.5kb sequence in clone 1 is the sequence for Retanef,
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respectively. Therefore, pVAX-RTN clone 1 was used as a negative control for further
experiments involving the expression of the Retanef protein. The orientation of the CMV
primer, forwards RTN primer, and backwards RTN primer can be seen in Figure 5. Prior
to doing PCR, the pVAX-RTN clones 1 and 2 were sent to Eurofins for gene sequencing,
and these results also confirmed that the 1.5kb sequence is the sequence for Retanef
(Appendix A).
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Figure 6 – Gel electrophoresis of pVAX-RTN clone 1 PCR products using forward
and reverse primers. A molecular weight ladder was loaded before the pVAX-RTN
clone 1 PCR products. Lane 1 contains the PCR products of pVAX-RTN clone 1, CMV
primer, and the reverse RTN primer. Lane 2 contains the PCR products of pVAX-RTN
clone 1, CMV primer, and forward RTN primer. Lane 3 is the positive control with the
PCR products of pVAX-RTN clone 1, reverse RTN primer, and forward RTN primer.

The PCR results for pVAX-RTN clone 2 show conclusive results which can be
seen in Figure 7. Lane 1 contains the PCR results for pVAX-RTN clone 1, reverse primer
for RTN, and a CMV primer. This lane shows a clear band indicating that the reverse
primer resulted in a successful amplification of pVAX-RTN clone 2. Lane 2 contains the
forward primer, CMV primer, and pVAX-RTN clone 2. This lane does not have a clear
band, which indicates the forward primer did not result in successful amplification of
pVAX-RTN clone 2. Lane 3 is a positive control that contains both forward and reverse
28

primers, and the results show a clear band indicating successful amplification of pVAXRTN clone 2. The results shown in Figure 7 in Lane 2 and Lane 3 indicate that the RTN
sequence in pVAX-RTN clone 2 is forwards, and the 1.5kb sequence in clone 2 is the
sequence for Retanef, respectively.
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Figure 7 – Gel electrophoresis of pVAX-RTN clone 2 PCR products using forward
and reverse primers. A molecular weight ladder was loaded before the pVAX-RTN
clone 1 PCR products. Lane 1 contains the PCR products of pVAX-RTN clone 2, CMV
primer, and the reverse RTN primer. Lane 2 contains the PCR products of pVAX-RTN
clone 2, CMV primer, and forward RTN primer. Lane 3 is the positive control with the
PCR products of pVAX-RTN clone 2, reverse RTN primer, and forward RTN primer.

Detection of SIV-Retanef Protein in Vero Cells via Immunofluorescence
After transfecting the pVAX-RTN clones into Vero cells, the expression of RTN
protein inside Vero cells was observed using immunofluorescence. The transfected cells
were stained with DAPI to analyze the location of the nuclei. Anti-HA-1 antibodies were
the 1° antibody and used to localize the Retanef protein, and antibodies tagged with FITC
were the 2° antibody and used to visualize the location of the 1° antibody. Vero cells
transfected with pVAX-RTN clone 1and Vero cells transfected with pVAX-RTN clone 2
both showed viable cells when stained with DAPI. However, cells stained with FITC and
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pVAX-RTN clone 1 did not fluoresce. The immunofluorescence results for Vero cells
stained with FITC and transfected with pVAX-RTN clone 2 showed localization of the
Retanef protein as indicated by the green fluorescence. These results shown in Figure 8
confirm that the transfection of pVAX-RTN clone 2 into Vero cells results in the
successful expression of Retanef protein. The transfection of pVAX-RTN clone 1 into
Vero cells does not produce Retanef protein. This was the expected result for pVAXRTN clone 1 because it was used as the negative control.

pVAX-RTN clone 1 w/DAPI

pVAX-RTN clone 2 w/DAPI

pVAX-RTN clone 1 w/FITC

pVAX-RTN clone 2 w/FITC

Figure 8 – Immunofluorescence analyses of Vero cells transfected with pVAX-RTN
clones 1 and 2. The nuclei were stained with DAPI (blue fluorescence). The Retanef
protein was stained with anti-HA-1 antibody and FITC-conjugated goat anti-mouse
antibody (green fluorescence). Localization of the Retanef protein and stained nuclei of
the cell is indicated with a white pointer arrow.
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Identification of SIV-Retanef Protein via Western Blotting
Western Blotting was used to confirm further that the protein identified during
immunofluorescence was Retanef. Vero cells transfected with pVAX-RTN clones 1 and
2 were solubilized, and the proteins were separated on a SDS-PAGE. After transferring
the proteins to a PVDF membrane, the protein of interest was identified using antibodies
in a chemiluminescence immunoassay. The 1° antibody used was a anti-HA-1 antibody,
and the 2° antibody used was an HRP-conjugated antibody. Lane 1 was the negative
control and contained proteins isolated from Vero cells transfected with pVAX-RTN
clone 1, and the results did not indicate the presence of the Retanef protein. Lane 2
contained the experimental group which contained proteins isolated from Vero cells
transfected with pVAX-RTN clone 2. This lane contained a definitive band around
55kDa, the estimated size of the Retanef protein. These results shown in Figure 9 indicate
that the protein isolated from Vero cells transfected with pVAX-RTN clone 2 reacts to
the anti-HA-1 antibody. Since the antibody can only identify the HA-tag on the Retanef
protein and not the protein itself, this experiment can only definitively confirm the
presence of the HA-tag. The next experiment further proves that the protein identified is
Retanef.
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Figure 9 – Western Blot of pVAX-RTN clones 1 and 2 using anti-HA-1 antibody and
HRP-conjugated anti-mouse antibody. Lane 1 has pVAX-RTN clone 1 as the negative
control. Lane 2 contains pVAX-RTN clone 2 and is the experiemental group. There is a
band around 55 kDa in lane 2; this is similar to the size of the Retanef protein.

Western Blotting using SIV monkey serum

Serum from monkeys infected with SIV was used to confirm the identity and
analyze the humoral response produced by the protein isolated from the transfected Vero
cells. SIV positive monkey serum was used against both clones, and the results are shown
in Figure 10 (A). SIV negative monkey serum was also used against both clones as a
negative control, and the results are shown in Figure 10 (B). Again, Vero cells transfected
with pVAX-RTN clone 1 were used as the negative control for the expression of RTN
protein, and the results for both SIV positive and SIV negative monkey serum showed no
indication of the Retanef protein. Vero cells transfected with pVAX- RTN clone 2
reacted with SIV positive monkey serum, and the results are indicated by a 55kDa band
found in lane 2 of Figure 10 (A). Vero cells transfected with pVAX-RTN clone 2
exposed to SIV negative monkey serum did not show any results and is indicated by the
absence of a band in lane 2 in Figure 10 (B). The results for this experiment confirmed
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that the protein produced by pVAX-RTN clone 2 is Retanef and that the protein is able to
produce a humoral response with SIV antibodies.

MW 1

2

MW 1

2

55 kDa

(A)
(B)
Figure 10 – Western Blot of pVAX-RTN clones 1 and 2 using SIV positive and SIV
negative monkey sera. Both figures have pVAX-RTN clone 1 in lane 1 as the negative
control, and pVAX-RTN clone 2 in lane 2 as the experimental group. (A) Monkey serum
from a confirmed SIV positive monkey was used as the primary antibody to confirm if
the protein isolated was an SIV protein. The protein identified had a band around
55kDa.(B) Monkey serum from a SIV negative monkey was used as the negative control.
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CONCLUSION
Throughout this research process, different methods were used to characterize a
plasmid-based DNA vaccine for SIV, and the results proved that the previously
constructed pVAX-RTN plasmid successfully produces the Retanef protein inside Vero
cells. The restriction digests and PCR resulted in successful identification of the identity
and orientation of the Retanef gene sequence inside the pVAX plasmid. PCR results with
pVAX-RTN clone 1 were only successful when the forwards RTN primer and CMV
primer were used. For pVAX-RTN clone 2, the backwards RTN primer and CMV primer
produced successful results. This validates that the pVAX-RTN clone 1 gene sequence
for RTN is in the backward direction, and that the pVAX-RTN clone 2 gene sequence for
RTN is in the forward direction. Following the conclusion made by PCR and restriction
digests, pVAX-RTN clone 1 was used as the negative control because the results showed
that the RTN gene sequence is backwards. This reverse gene sequence does not allow
expression of the protein. The experimental group was pVAX-RTN clone 2, which is
expected to successfully express Retanef protein due to its forward RTN gene sequence.
Localization and identification of the Retanef protein was successfully observed
via immunofluorescence and western blotting using antibodies. However, the antibodies
were only specific to the HA-1 tag on the Retanef protein, which does not prove that the
Retanef protein is what was identified by immunofluorescence and western blotting. In
order to prove that the protein identified was Retanef, serum from SIV positive monkeys
was used in a western blot, and the results indicated that there was a reaction between
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SIV positive serum and the isolated Retanef protein. This further proves that the protein
expressed inside the transfected Vero cells is indeed Retanef.
The SIV positive serum produces a general reaction towards any SIV antigen; this
experiment did not indicate if the protein expressed was rev, tat, or nef. Further studies
can be conducted to isolate and determine the identity of the protein expressed. The
results for the SIV positive serum also conclude that the protein expressed by the pVAXRTN plasmid is successful in reacting to an immune response against SIV. Additionally,
the cellular and humoral immune responses can be analyzed in further studies by
challenging non-human primates with the pVAX-RTN plasmid. The pVAX-RTN
plasmid proves to be a good candidate for expressing Retanef protein inside Vero cells,
and further studies should be done to observe T-cell response. The results of this study
show that the pVAX-RTN plasmid is a good candidate for a DNA vaccine against SIV,
however further studies need to be conducted to observe the safety and efficacy of this
vaccine as a therapeutic and prophylactic treatment for SIV-infected non-human
primates.
Since most vaccine research against HIV has focused on using structural genes,
the results of this experiment may encourage further research on including regulatory
proteins in future vaccines against HIV. The data collected in this experiment provides
strong evidence that a corresponding HIV vaccine with the rev, tat, and nef regulatory
proteins should be evaluated. The overall goal of this experiment was to contribute
towards HIV research and finding preventative treatments and vaccines for HIV by using
SIV as a model.
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APPENDIX

>PVAX_RTN1_CMV_CMVf Sample_Name=PVAX_RTN1_CMV_CMVf Chromat_id=10441183
Read_id=10350013 Version=1 Length=956
NNNNNNNNNNNAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATA
CGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCTTA
TCAGGCCAGGCTGGCGTAGTCGGGCACGTCGTAGGGGTAGCGCTTGCGGCTCTGCTCGTAGCAGATGCC
CAGGCCCTTCTTCAGGAAGCAGAACTGGCAGTGGTAGCAGCACTTCTTGCAGTAGCAGGTGTTGTAGCA
GGCCTCCAGGGGGCGGTACAGCTGGCTCAGGATCTCCTCGCCCAGGTTGGCGCTCTCGGGGGTGGTGG
CGTCGGCCTCCAGGATGCAGCTGCTGCGCTCGTTGCTGCTCTCCAGGCTGTTCTCCTGCTCGCGCAGGGG
GGTTTCGAGGTAGATATCCAGAATCCTGTGGCGGCGGGCGCTGTAGTAGATGCCCTCCAGGCCGCCCTT
CTCCTTGATGAAGTGGCTCATGTCGATGGCCAGCTTGTAGCTCATGGTGCGCAGGGGCACCTTGGGGCG
CACGCTCACGCCCACCAGGTCGTCGTCCTCCTCGTCGATGTCGTCCATGTTCTGCTTGCGGTAGGCCAGCT
TCTCGCGCTCCTCGGCGGGGTTGCGCCAGGGGGTGTTCATGTACTGGCCCTGGTTGTACTTCTGGCCCTC
GCAGCTCAGGCTGCTCAGGCCCTTGTCCAGGCCGCCGGGGCTCTGGCTGTAGCCGTCCTCCACCTCGCCC
AGCAGGCGGCCGTAGGTCTCGCCCCGGGCGCGCAGCAGGCGCTGGCGCAGGTCGCCGCTGGGGCGGCT
GCGGCGCATGCTGATGGCGTCGACGCCGCCACTAGTGCGGCCCAGGCCCGGGGGCGGTGGCCCCGGCC
TTCTCCCCGGTCTCCTTCTTGGCCTTCTCGGGCTGGNANNGNCGGGNGCGNTGGGG

Figure A-1- Gene sequencing results for pVAX-RTN clone 1. This figure shows the
direction of the TGA stop site in relation to the CMV promoter in pVAX-RTN clone 1.
Since this is sequence is in the reverse direction to the CMV promoter, the sequencing
results are the reverse complement of the Retanef sequence. The highlighted portion is
the reverse complement of the TGA stop site.
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>PVAX_RTN2_CMV_CMVf Sample_Name=PVAX_RTN2_CMV_CMVf Chromat_id=10441185
Read_id=10350035 Version=1 Length=925
NNNNNNNNNNNNNNAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATT
AATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATC
CGCCACCATGAGCAGCCACGAGCGCGAGGAGGAGCTGCGCAAGCGCCTGCGCCTGATCCACCTGCTGC
ACCAGACCATCGACAGCTACCCCACCGGCCCCGGCACCGCCAACCAGCGCCGCCAGTGGCAGCAGCTGC
TGGCCCTGGCCGACCGCATCTACAGCTTCCCCGACCCCCCCACCGACACCCCCCTGGACCTGGCCATCCA
GCAGCTGCAGAACCTGGCCATCGAGAGCATCCCCGACCCCCCCACCAACACCCCCGAGGCCCTGTGCGA
CCCCACCAAGGGCAGCCGCAGCCCCCAGGACCACCGCATCCTGGACATCTACCTGGAGAAGGAGGAGG
GCATCATCCCCGACTGGCAGGACTACACCAGCGGCCCCGGCATCCGCTACCCCAAGACCTTCGGCTGGCT
GTGGAAGCTGGTGCCCGTGAACGTGAGCGACGAGGCCCAGGAGGACGAGGAGCACTACCTGATGCACC
CCGCCCAGACCAGCCAGTGGGACGACCCCTGGGGCGAGGTGCTGGCCTGGAAGTTCGACCCCACCCTGG
CCTACACCTACGAGGCCTACGTGCGCTACCCCGAGGAGTTCGGCAGCAAGAGCGGCCTGAGCGAGCGCC
GCACCCCCAAGAAGGCCAAGGCCAACACCAGCAGCGCCAGCAACAACCGCCTGATCCCCAACCGCACCC
GCCACTGCCAGCCCGAGAAGGCCAAGAAGGAGACCGTGGAGAAGGCCNNGGGCCACCGCCCCCGGCN
NGGGGCGCCCNNNNGGCGGNNNCNANNCNTT

Figure A-2- Gene sequencing results for pVAX-RTN clone 2. This figure shows the
direction of the ATG start site in relation to the CMV promoter in pVAX-RTN clone 2.
The ATG start site is in forwards orientation to the CMV promoter.
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